Fortune

A Biotech Boom in China? Not Just Yet

Chinese biopharma stocks have lucrative potential, but realizing gains will involve some growing pains.
BeiGene’s share price has fallen 11.3% since its IPO.

RECENT REGULATORY changes in China have led to an outpouring of enthusiasm from investors and biopharmaceutical companies looking to gain a foothold in one of the world’s major markets—a

You're reading a preview, sign up to read more.

More from Fortune

Fortune16 min readScience
Racing a Rising Tide
ON A RADIANT SUMMER DAY, all looks precisely right on the shore of Switzerland’s Lake Zurich, at the headquarters of global insurance behemoth Swiss Re. The postcard-perfect harbor bustles with bronzed sunbathers, dark-hulled yachts, and picnickers s
Fortune2 min readTech
A.I. Vs. The Wolves Of Wall Street
AN INVESTOR SUBMITS a mountain of online orders to sell shares in a grocery chain. It may look like another routine trade, but it’s a scam. What he’s actually done is spook others into selling their stock in the company, causing its value to tumble.
Fortune4 min read
When Cash Cushions Your Fall
THE CURRENT BULL MARKET in stocks is several months past its 10th birthday, and prognosticators have been predicting its demise for at least half its life. You can hardly blame them for being early: Historically, the average bull market has lasted le